Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A One-year Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients With Moderately to Severely Active Crohn's Disease (CD) in China

NCT05394805 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05394805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05394805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A One-year Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients With Moderately to Severely Active Crohn's Disease (CD) in China
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
June 29, 2022
Completion date
December 26, 2024
Enrollment
156 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease